overcoming bias and systematic errors in next generation sequencing data克服偏见和下一代测序数据中系统误差.pdfVIP

Taub et al. Genome Medicine 2010, 2:87 /content/2/12/87 CO M M E N TA R Y Overcoming bias and systematic errors in next generation sequencing data 1 2 1 Margaret A Taub* , Hector Corrada Bravo and Rafael A Irizarry* FDA-approved clinical diagnostic tests, including Abstract MammaPrint, and Pathwork’s Tissue of Origin test [7,8]. Considerable time and eort has been spent in With high-throughput sequencing still in its infancy, developing analysis and quality assessment methods many questions remain to be addressed before any hope to allow the use of microarrays in a clinical setting. As of achieving approval for clinical applications is is the case for microarrays and other high-throughput warranted. Although a study on the scale of the MAQC technologies, data from new high-throughput analyses for microarrays has yet to be carried out for sequencing technologies are subject to technological sequencing (although one is in the works), there is and biological biases and systematic errors that can already evidence that similar technical biases are present impact downstream analyses. Only when these issues in sequencing data, and these will need to be understood can be readily identied and reliably adjusted for will and adjusted for to enable use of these new technologies clinical applications of these new technologies be in a clinical setting. In this commentary, we present some feasible.